DENVER, March 31 Global Med Technologies(R),Inc. ("Global Med" or the "Company") (OTC Bulletin Board: GLOB), aninternational e-Health, medical information technology company, todayannounced the signing of a Purchase Agreement to acquire Inlog, SA, and itsGerman and related subsidiaries ("Inlog"), a private European medical softwarefirm, for a maximum of $11.5 million in a combination of cash, stock andearnout. Inlog's shareholders must use $500,000 of the cash proceeds topurchase Global Med common stock in the open market within three months of theclosing. Inlog's unaudited revenues for their fiscal year ended June 30, 2007were approximately euro 7.3 million* or about $11.4 million at currentexchange rates, with EBITDA of approximately euro 770,000* or approximately$1.2 million. Global Med will utilize a combination of existing cash and debtto pay for the transaction.
Inlog, based in Lyon, France, with additional operations in Grenoble,France, Munich and Alzey, Germany, is a leading European provider of donorcenter and transfusion information management systems as well as laboratoryinformation systems and other ancillary medical software systems. Thetransaction is expected to close in the second quarter of 2008. Inlog'smanagement is planning to stay with the Company.
Chairman and CEO of Global Med Technologies, Inc., Michael I. Ruxin, M.D.,stated, "The acquisition of Inlog by Global Med is a transforming event in thehistory of our Company." Dr. Ruxin continued, "At the completion of thisacquisition, we will truly be a global company, with blood and laboratorysoftware applications in 20 countries (in the US, Canada, Caribbean, EuropeanUnion, Africa, French Polynesia, and New Caledonia). This includes 582 donorcenter sites, 458 hospital sites and 360 laboratories world-wide, for a totalof 1,400 sites. From our perspective, our high quality people, productivityand services, coupled with our high-touch philosophy to our current and futurecustomers, through our Service 360(TM) commitment, will continue to allow usto grow our Company in the global marketplace." Dr. Ruxin added, "Thestructure of this transaction is expected to be accretive, exclusive offinancing costs, in the first full year of operations. This acquisition isstrategically important to Global Med as the international marketplaceprovides a platform for Global Med's continued growth."
Inlog's product line consists of five primary products: EdgeBlood** (alsoknown as CTS Serveur, for the donor center marketplace), EdgeTrack** (for thehospital transfusion marketplace), EdgeLab (Laboratory Information System"LIS"), EdgeCell (Cellular Therapy for tissue banks, stem cell centers andcord blood centers), and SAPA (supports regulatory compliance and documentmanagement). Inlog is ISO 9001:2000 certified and their products havereceived the NF/ISO 25051/12119 certification guaranteeing the highest levelof quality regarding the design, the testing and validation of the software,the documentation quality and the quality of support and maintenance.
Inlog has been developing, implementing, and supporting its blood bankinformation management solutions since 1992 with over 700 sites in 15countries using its own products. Inlog recently completed the nationalinstallation of its EdgeBlood product in France. All 2.2 million French blooddonations flow through Inlog's products in France including blood collections,infectious disease testing, component manufacturing and distribution. Inaddition to France, Inlog has substantial blood center and transfusion marketshare in Germany, Austria, Belgium and Switzerland, as well as installationsin Greece and Monaco. Some of Inlog's notable clients are the French BloodEstablishment (Etablissement Francais du Sang), the Bade-Wurttemberg-HessenRed Cross, the Bavarian Red Cross